1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2011. www.goldcopd.org

2. Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5: 343–349.

3. O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax 2006; 61; 354–361.

4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.

5. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.

6. Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–1455.

7. Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224–1238.

8. Smeeth L., Thomas S.L., Hall A.J. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351: 2611–2618.

9. Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. J.A.M.A. 1995; 274: 1852–1857.

10. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.

11. Parker C.M., Voduc N., Aaron S.D. et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420–428.

12. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.

13. Spencer S., Jones P.W., GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–593.

14. Gross N.J., Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease, comparison with a beta-adrenergic agent. Am. Rev. Respir. Dis. 1987; 136: 1091–1094.

15. Karpel J.P. The use of anticholinergic drugs in acute exacerbations of chronic obstructive pulmonary disease. In: Gross N.J., ed. Anticholinergic therapy in obstructive airways disease. London: Franklin Scientic Publications; 1993. 145–154.

16. Fernandez A., Muñoz J., Calle B. et al. Comparison of one versus two bronchodilators in ventilated COPD patients. Int. Care Med. 1994; 20: 199–202.

17. O'Driscoll B.R., Taylor R.J., Horsley M.G. et al. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 2: 1418–1420.

18. Boe J., Dennis J.H., O'Driscoll B.R. et al. European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. 2001; 18: 228–242.

19. Авдеев С.Н., Нуралиева Г.С., Батын С.З. и др. Эффективность комбинированной терапии ингаляционными β2-агонистами и антихолинергическими препаратами при тяжелом обострении хронической обструктивной болезни легких: рандомизированное контролируемое исследование. Пульмонология 2007; 3: 56–65.

20. Bach P.B., Brown C., Gelfand S.E., McCrory D.C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann. Intern. Med. 2001; 134: 600–620.

21. Авдеев С.Н. Небулайзерная терапия обструктивных заболеваний легких. Consilium Medicum 2011; 13 (3): 36–43.

22. Willaert W., Daenen M., Bornans P. et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur. Respir. J. 2002; 19: 928–935.

23. Guerin C., Chevre A., Dessirier P. et al. Inhaled fenoterolipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1036–1042.